Skip to main content
Hubei Hongyuan Pharmaceutical Technology Co.,Ltd. logo

Hubei Hongyuan Pharmaceutical Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 301246 ISIN · CNE100005ZB9 LEI · 30030044K9FMVD6UPL26 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 397 across all filing types
Latest filing 2026-06-01 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301246

About Hubei Hongyuan Pharmaceutical Technology Co.,Ltd.

https://www.hbhypharm.com

Hubei Hongyuan Pharmaceutical Technology Co., Ltd. specializes in the research, development, production, and distribution of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and fine chemicals. The company is a significant global supplier of nitroimidazole derivatives, including metronidazole, tinidazole, and ornidazole. Its product portfolio extends to organic chemical raw materials such as glyoxal and glyoxalic acid. Additionally, the firm has expanded its operations into the new energy sector, focusing on the production of lithium battery materials like lithium hexafluorophosphate. By leveraging integrated production chains and advanced manufacturing processes, the company serves diverse markets across the pharmaceutical, chemical, and energy industries, maintaining a focus on technical innovation and large-scale supply capabilities.

Recent filings

Filing Released Lang Actions
关于缴纳税款的公告
Regulatory Filings Classification · 85% confidence The document is a brief corporate announcement regarding the company’s payment of enterprise income tax, including impact and risk disclosures. It does not contain any financial statements, it is not soliciting votes or presenting AGM materials, nor is it a report like an annual or interim report. This falls under a general regulatory announcement/compliance disclosure. Therefore, it is classified as a Regulatory Filing (RNS).
2026-06-01 Chinese
第五届董事会第二次会议决议公告
Board/Management Information Classification · 91% confidence The document is an announcement of the board of directors’ meeting resolutions (the 5th Board’s 2nd meeting). It details board decisions, the voting results, and follow-up actions (setting up a fundraising account, project changes). This fits under Board/Management Information (MANG).
2026-06-01 Chinese
上海市通力律师事务所关于湖北省宏源药业科技股份有限公司2025年年度股东会的法律意见书
AGM Information Classification · 93% confidence The document is a legal opinion letter (“法律意见书”) from an external law firm regarding the convening, procedures, attendance, voting process, and results of the company’s 2025 Annual General Meeting. It is part of the meeting’s official materials (as stated, it will be filed and published along with other AGM documents). This aligns with the AGM Information category, which covers materials shared at the Annual General Meeting. It is not merely a vote results announcement (though it includes results), nor is it a proxy statement, regulatory notice, or financial report.
2026-05-20 Chinese
关于公司董事会完成换届选举及聘任高级管理人员的公告
Board/Management Information Classification · 97% confidence The document is a corporate announcement detailing the results of the board re-election (换届选举) and the appointment of senior management personnel, including names and terms for new directors, independent directors, committee members, and C-suite officers. This clearly falls under “Board/Management Information” (category MANG).
2026-05-20 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the 2025 annual general meeting resolutions for 湖北省宏源药业科技股份有限公司, detailing attendance, each motion voted on, and the vote counts (for/against/abstain). This matches the category for declaration of voting results at a general meeting. Therefore, it is classified as Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-20 Chinese
第五届董事会第一次会议决议公告
Board/Management Information Classification · 89% confidence The document is a public announcement of the resolutions from the first meeting of the fifth board of directors of Hubei Hongyuan Pharmaceutical Technology Co., Ltd. It details the election and appointment of the chairman, general manager, vice-general managers, and other senior management positions. This clearly falls under board/management changes rather than a full annual or interim report, earnings release, or regulatory filing. Therefore, it should be classified as a Board/Management Information announcement.
2026-05-20 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.